PL2814829T3 - Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania - Google Patents

Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania

Info

Publication number
PL2814829T3
PL2814829T3 PL13704871T PL13704871T PL2814829T3 PL 2814829 T3 PL2814829 T3 PL 2814829T3 PL 13704871 T PL13704871 T PL 13704871T PL 13704871 T PL13704871 T PL 13704871T PL 2814829 T3 PL2814829 T3 PL 2814829T3
Authority
PL
Poland
Prior art keywords
conjugates
methods therefor
enediyne compounds
enediyne
compounds
Prior art date
Application number
PL13704871T
Other languages
English (en)
Inventor
Naidu S. Chowdari
Sanjeev Gangwar
Bilal Sufi
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47722570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2814829(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL2814829T3 publication Critical patent/PL2814829T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13704871T 2012-02-13 2013-02-08 Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania PL2814829T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261598143P 2012-02-13 2012-02-13
US201261653785P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
PL2814829T3 true PL2814829T3 (pl) 2017-06-30

Family

ID=47722570

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13704871T PL2814829T3 (pl) 2012-02-13 2013-02-08 Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania

Country Status (31)

Country Link
US (2) US8709431B2 (pl)
EP (1) EP2814829B1 (pl)
JP (1) JP6113194B2 (pl)
KR (1) KR101660146B1 (pl)
CN (1) CN104220441B (pl)
AR (1) AR089972A1 (pl)
AU (1) AU2013221873B2 (pl)
BR (1) BR112014019990A8 (pl)
CA (1) CA2864420C (pl)
CL (1) CL2014002096A1 (pl)
CO (1) CO7061078A2 (pl)
CY (1) CY1118899T1 (pl)
DK (1) DK2814829T3 (pl)
EA (1) EA027925B1 (pl)
ES (1) ES2615268T3 (pl)
HK (1) HK1204326A1 (pl)
HR (1) HRP20170334T1 (pl)
HU (1) HUE033704T2 (pl)
IL (1) IL233965B (pl)
LT (1) LT2814829T (pl)
MX (1) MX350539B (pl)
PE (1) PE20141791A1 (pl)
PL (1) PL2814829T3 (pl)
PT (1) PT2814829T (pl)
RS (1) RS55763B1 (pl)
SG (1) SG11201404667XA (pl)
SI (1) SI2814829T1 (pl)
SM (1) SMT201700137T1 (pl)
TW (1) TW201336851A (pl)
WO (1) WO2013122823A1 (pl)
ZA (1) ZA201406723B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2015023879A1 (en) * 2013-08-14 2015-02-19 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
SG11201607818WA (en) 2014-03-20 2016-10-28 Bristol Myers Squibb Co Stabilized fibronectin based scaffold molecules
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗cd73抗體及其用途
CN114591420A (zh) 2014-11-25 2022-06-07 百时美施贵宝公司 用于成像的新型pd-l1结合多肽
US10336766B2 (en) * 2015-01-08 2019-07-02 The Scripps Research Institute Anticancer drug candidates
ES2736106T3 (es) 2015-03-10 2019-12-26 Bristol Myers Squibb Co Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos
MX2017015041A (es) 2015-05-29 2018-02-26 Squibb Bristol Myers Co Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos.
EP3733698A1 (en) 2015-09-23 2020-11-04 Bristol-Myers Squibb Company Glypican-3 binding fibronectin based scafflold molecules
EP3165237B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
KR20180089433A (ko) 2015-12-21 2018-08-08 브리스톨-마이어스 스큅 컴퍼니 부위-특이적 접합을 위한 변이체 항체
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
CN106267188B (zh) * 2016-08-15 2025-06-17 深圳大学 小分子免疫激动剂偶联pd-1抗体的新型抗体及其在抗肿瘤中的应用
WO2018048975A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CA3064321A1 (en) 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN111683686A (zh) * 2017-12-06 2020-09-18 西纳福克斯股份有限公司 烯二炔缀合物
CN110183659B (zh) * 2018-02-21 2022-04-26 香港科技大学 含有杂环的聚合物、其制备方法及其应用
KR20210096167A (ko) 2018-11-28 2021-08-04 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
WO2020112588A1 (en) 2018-11-30 2020-06-04 Bristol-Myers Squibb Company Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses
US12478686B2 (en) 2018-12-12 2025-11-25 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
CN114174305A (zh) * 2019-05-22 2022-03-11 德克萨斯大学系统董事会 用于治疗癌症的官能化的金卡宾萘醌络合物
US20240377413A1 (en) 2019-09-16 2024-11-14 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
US20240261426A1 (en) 2021-06-28 2024-08-08 Byondis B.V. Conjugates comprising phosphoantigens and their use in therapy

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US5144011A (en) 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4698420A (en) 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
US5162330A (en) * 1990-11-05 1992-11-10 Bristol-Myers Squibb Co. Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
CN1463270A (zh) 2001-05-31 2003-12-24 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
KR100829283B1 (ko) 2002-01-09 2008-05-13 메다렉스, 인코포레이티드 Cd30에 대한 인간 모노클로날 항체
EP1613274B1 (en) 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
UY28424A1 (es) 2003-07-22 2005-02-28 Schering Ag Anticuerpos rgi y usos de los mismos.
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
US8170637B2 (en) * 2008-05-06 2012-05-01 Neurosky, Inc. Dry electrode device and method of assembly
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
MXPA06013413A (es) 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2416136T3 (es) 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
AU2006294663B2 (en) 2005-09-26 2012-03-22 Medarex, Inc. Human monoclonal antibodies to CD70
WO2007038868A2 (en) 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
ES2375843T3 (es) 2005-10-26 2012-03-06 Medarex, Inc. Procedimientos y compuestos para la preparación de an�?logos de cc-1065.
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
JP5714212B2 (ja) 2005-12-08 2015-05-07 メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. O8eに対するヒトモノクローナル抗体
SG177194A1 (en) 2005-12-08 2012-01-30 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies
KR100869414B1 (ko) 2005-12-13 2008-11-21 야마하 가부시키가이샤 건반식 음판 타악기용의 음판 및 그 제조방법, 음판타악기의 음원 유닛 및 건반식 타악기
CA2662752C (en) 2006-09-08 2016-04-12 Ambrx, Inc. Site specific incorporation of non-natural amino acids by vertebrate cells
NZ578064A (en) 2006-12-01 2012-01-12 Medarex Inc Human antibodies that bind cd22 and uses thereof
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CN101616911A (zh) 2007-02-21 2009-12-30 梅达莱克斯公司 具有单个氨基酸的化学连接物及其偶联物
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
AU2008308956B2 (en) 2007-10-01 2013-03-14 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof

Also Published As

Publication number Publication date
EP2814829A1 (en) 2014-12-24
EP2814829B1 (en) 2016-12-07
ES2615268T3 (es) 2017-06-06
MX2014009234A (es) 2014-11-10
AU2013221873A1 (en) 2014-10-02
CN104220441B (zh) 2017-03-29
DK2814829T3 (en) 2017-03-20
MX350539B (es) 2017-09-08
HRP20170334T1 (hr) 2017-04-21
JP6113194B2 (ja) 2017-04-12
AR089972A1 (es) 2014-10-01
LT2814829T (lt) 2017-02-27
KR101660146B1 (ko) 2016-09-26
US8709431B2 (en) 2014-04-29
CA2864420A1 (en) 2013-08-22
US20140193438A1 (en) 2014-07-10
US20130209494A1 (en) 2013-08-15
CN104220441A (zh) 2014-12-17
IL233965B (en) 2018-01-31
CA2864420C (en) 2016-11-15
RS55763B1 (sr) 2017-07-31
SI2814829T1 (sl) 2017-02-28
HK1204326A1 (en) 2015-11-13
HUE033704T2 (en) 2017-12-28
EA201491447A1 (ru) 2014-11-28
WO2013122823A1 (en) 2013-08-22
KR20140120374A (ko) 2014-10-13
PT2814829T (pt) 2017-02-15
EA027925B1 (ru) 2017-09-29
US9156850B2 (en) 2015-10-13
CL2014002096A1 (es) 2014-11-28
ZA201406723B (en) 2016-05-25
AU2013221873B2 (en) 2016-11-17
BR112014019990A8 (pt) 2017-07-11
TW201336851A (zh) 2013-09-16
CY1118899T1 (el) 2018-01-10
CO7061078A2 (es) 2014-09-19
SG11201404667XA (en) 2014-09-26
SMT201700137T1 (it) 2017-05-08
JP2015508074A (ja) 2015-03-16
PE20141791A1 (es) 2014-11-19
BR112014019990A2 (pl) 2017-06-20

Similar Documents

Publication Publication Date Title
HUS2300020I1 (hu) Pirrolobenzodiazepin-antitest konjugátumok
ZA201406723B (en) Enediyne compounds, conjugates thereof, and uses and methods therefor
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
PT2920167T (pt) Compostos de hidrazinil-indol e conjugados
EP2850059A4 (en) CONJUGATES OF MEDICATION, METHODS OF CONJUGATION AND USE THEREOF
GB201304967D0 (en) .
GB201204183D0 (en) .
EP2902677A4 (en) SLIDING PART
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
ZA201408914B (en) Conjugation reagents
IL237710A0 (en) Padlock
IL237636A0 (en) new uses
ZA201409119B (en) Polymer-nsaid conjugate
GB2501004B (en) Two piece drysuit
GB2500883B (en) Improved saw-horse
GB201300194D0 (en) Padlock
GB201207426D0 (en) .
GB201206865D0 (en) .
GB201206866D0 (en) .
GB201205844D0 (en) .
GB201200117D0 (en) .
GB201218713D0 (en) Improved padlock
GB201222799D0 (en) H.o.d
ZA201305187B (en) Improved brattice
GB201212393D0 (en) Novel combination